Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: A British society for haematology guideline
source: British Journal of Haematology
year: 2018
authors: Qureshi A, Kaya B, Pancham S, Keenan R, Anderson J, Akanni M, Howard J
summary/abstract:Sickle cell disease (SCD) is a generic term for an inherited group of disorders that includes homozygous sickle cell anaemia (SS), sickle cell/haemoglobin C (SC) sickle cell/β-thalassemia (S/β thal) and other compound heterozygous conditions. SCD is characterised by the presence of the mutated β‐globin gene, HBBs (also termed βs‐globin).
On de‐oxygenation, this forms a polymeric structure resulting in deformed, rigid red blood cells, and is associated with a chronic haemolytic anaemia due to shortened red cell life span and vaso‐occlusion causing frequent episodes of severe bony pain (vaso‐occlusive crises) and other acute and chronic complications. These include an increased risk of stroke, pulmonary hypertension, acute and chronic lung damage, chronic renal failure and leg ulcers.
Fetal haemoglobin (haemoglobin F, HbF, α2ϒ2) is protective against these complications and infants are relatively protected in the first few months of life before HbF in infancy is replaced by HbS (α2βS2) rather than adult haemoglobin (HbA, α2β2). Co‐inheritance of raised HbF levels is also associated with a milder phenotype.
organization: Oxford University Hospital NHS Trust, United Kingdom; Barts Health NHS Trust, United Kingdom; Sandwell and West Birmingham NHS Trust, United Kingdom; Alderhey Children's Hospital NHS Trust, United Kingdom; Imperial College Healthcare NHS Trust, United Kingdom; Milton Keynes Hospital NHS Trust, United Kingdom; Guys and St Thomas's NHS Foundation Trust, United Kingdom
DOI: 10.1111/bjh.15235
read more full text
+myBinderRelated Content
-
Hydroxyurea: The Best Hope for Sickle Cell Anemia Patientshttps://www.youtube.com/watch?v=L_xSgQWj...
-
The Hazards of Hazardous Drug Labeling: Time to Revisit Hydroxyurea?Despite benefits in reducing pain crises...
-
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan AfricaBackground: Hydroxyurea has proven saf...
-
SCD Patients Receiving Hydroxyurea in the U.S. Still Face Many ChallengesPeople with sickle cell disease (SCD) tr...
-
SCA Therapy Hydroxyurea Doesn’t Boost Malaria Risk in Sub-Saharan Africa, Study FindsHydroxyurea, a treatment recommended for...
-
Sickle Cell Disease Research Shows Progress in Preventing Related Complications and DeathStudies aim to limit pain crises, preven...
-
Pediatric sickle cell study stopped early due to positive resultsA national sickle cell disease study inv...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.